scispace - formally typeset
P

P. A. Woods

Researcher at Centers for Disease Control and Prevention

Publications -  16
Citations -  5158

P. A. Woods is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Rotavirus & Serotype. The author has an hindex of 16, co-authored 16 publications receiving 5047 citations.

Papers
More filters
Journal ArticleDOI

Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens.

TL;DR: A PCR typing method was devised in which each human serotype virus produced a characteristic segment size, readily identifiable in agarose gels, which provided a rapid and efficient means of obtaining large quantities of cDNA suitable for sequencing, cloning, and other genetic studies, precluding the need for cell culture and virus purification.
Journal ArticleDOI

Identification of group A rotavirus gene 4 types by polymerase chain reaction.

TL;DR: The results suggest that gene 4 typing will be useful in providing more a complete characterization of HRV strains of epidemiologic or vaccine-related interest.
Journal ArticleDOI

Review Of G And P Typing Results From A Global Collection Of Rotavirus Strains: Implications For Vaccine Development

TL;DR: These studies indicate that while rotavirus strains have limited diversity in many settings, reassortment between common and uncommon serotypes or animal strains can arise in some settings and, thus, lead to unusual diversity.
Journal ArticleDOI

The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden.

TL;DR: A rotavirus vaccine program will require improved surveillance, including the timely collection of data from sentinel hospitals, in which a diagnosis of rotav virus can be established or ruled out for all children hospitalized for diarrhea.
Journal ArticleDOI

Evidence of High-Frequency Genomic Reassortment of Group A Rotavirus Strains in Bangladesh: Emergence of Type G9 in 1995

TL;DR: The data suggest that a vaccine must provide protection against type G9 RVs as well as against the four major G types because G9 strains constituted 16% of the typeable RV strains and have predominated since 1996.